Guided Therapeutics (GTHP) Common Equity (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Common Equity for 16 consecutive years, with -$6.0 million as the latest value for Q4 2025.
- Quarterly Common Equity fell 22.72% to -$6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.0 million through Dec 2025, down 22.72% year-over-year, with the annual reading at -$6.0 million for FY2025, 22.72% down from the prior year.
- Common Equity hit -$6.0 million in Q4 2025 for Guided Therapeutics, down from -$5.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$2.7 million in Q3 2022 to a low of -$8.0 million in Q1 2021.
- Historically, Common Equity has averaged -$5.0 million across 5 years, with a median of -$5.0 million in 2022.
- Biggest five-year swings in Common Equity: skyrocketed 65.78% in 2022 and later tumbled 40.78% in 2024.
- Year by year, Common Equity stood at -$5.4 million in 2021, then surged by 47.05% to -$2.9 million in 2022, then crashed by 32.02% to -$3.8 million in 2023, then fell by 28.46% to -$4.9 million in 2024, then fell by 22.72% to -$6.0 million in 2025.
- Business Quant data shows Common Equity for GTHP at -$6.0 million in Q4 2025, -$5.7 million in Q3 2025, and -$5.5 million in Q2 2025.